PURPOSE Iadademstat is a novel, highly potent, and selective inhibitor of LSD1 (KDM1A), with preclinical in vitro and in vivo antileukemic activity. This study aimed to determine safety and tolerability of iadademstat as monotherapy in patients with relapsed/refractory acute myeloid leukemia (R/R AML). METHODS This phase I, nonrandomized, open-label, dose-escalation (DE), and extension-cohort (EC) trial included patients with R/R AML and evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antileukemic activity of this orally bioavailable first-in-class lysine-specific demethylase 1 inhibitor. RESULTS Twenty-seven patients were treated with iadademstat on days 1 to 5 (5-220 µg/m2/d) of each week in 28-day cycles in a DE phase that resulted in a recommended dose of 140 µg/m2/d of iadademstat as a single agent. This dose was chosen to treat all patients (n = 14) in an EC enriched with patients with MLL/KMT2A-rearranged AML. Most adverse events (AEs) were as expected in R/R AML and included myelosuppression and nonhematologic AEs, such as infections, asthenia, mucositis, and diarrhea. PK data demonstrated a dose-dependent increase in plasma exposure, and PD data confirmed a potent time- and exposure-dependent induction of differentiation biomarkers. Reductions in blood and bone marrow blast percentages were observed, together with induction of blast cell differentiation, in particular, in patients with MLL translocations. One complete remission with incomplete count recovery was observed in the DE arm. CONCLUSION Iadademstat exhibits a good safety profile together with signs of clinical and biologic activity as a single agent in patients with R/R AML. A phase II trial of iadademstat in combination with azacitidine is ongoing (EudraCT No.: 2018-000482-36).
In preclinical studies, LSD1 inhibitors derived from tranylcypromine were active in acute myeloid leukemia models, particularly in the MLL-translocated subtype. We now report the safety, PK and PD properties of ORY-1001 (a potent and selective inhibitor of LSD1) in a multicenter phase I study (EUDRACT nº 2013-002447-29). The primary objective was to assess safety and tolerability in relapsed or refractory acute leukemia (RR-AL). Secondary objectives were to a) characterize PK, b) to monitor a panel of surrogate PD markers for target engagement and c) assess clinical response. Patients ≥16yr with RR-AL, ECOG PS ≤2 and life expectancy >8wk were eligible. ORY-1001 was administered orally once daily in a 28 day cycle (5d ON/2d OFF x4wk). Plasma ORY-1001 levels were analyzed by HPLC-MS/MS. Blood leukocyte expression of candidate differentiation PD biomarkers was determined by qRT-PCR. Twenty-seven subjects (mean age 66.5, range 40-81; gender 19 M/8F) were recruited into the dose escalation phase (26 - RR-AML; 1 - RR-ALL). Mean time since initial diagnosis was 12.6 months and since last treatment was 2.1 months. Twenty patients completed cycle 1, 9 started cycle 2 with 3 completions and 3 started and completed cycle 3. The most frequent ADR was thrombocytopenia (7 events, 5 subjects). Twenty-two subjects experienced 32 SAEs of which two (Cohort 8 - 220 µg/m2/d) were considered possibly related to ORY-1001: grade 5 lobar pneumonia and grade 3 febrile neutropenia (in combination with grade 2 fatigue and grade 2 erythema multiforme). These were considered dose limiting toxicities. Consequently the recommended dose for the extension phase was established at 140 μg/m2/d. At the end of the dose escalation phase, 358 treatment emergent AEs were reported. The most frequent were asthenia (16 events, 12 subjects), febrile neutropenia (15 events, 13 subjects), constipation (12 events, 9 subjects) and peripheral oedema (11 events, 8 subjects). ORY-1001 plasma concentration increased with dose across cohorts. At 140 µg/m2/d (recommended dose) on d1 mean±SD Cmax was 13.1±7.2 and mean±SD AUC (0-24h) was 181.7±61.3pg.hr/mL. On d5 mean±SD Cmax was 42.2±27 and mean±SD AUC (0-24h) 723.3±341.5pg.hr/mL. PD biomarker response varied due to differences in disease genetics and circulating blast percentages. Nevertheless select biomarkers demonstrated time and dose dependent response profiles in individual patients. For example, PI16 (peptidase inhibitor 16; or CRISP-9) levels were induced in cohort 7 (140 µg/m2/d). Maximum PI16 induction was seen at 18hr on d1, pre-dose levels remained high on d5 and were sustained through the OFF period until pre-dose on d8. An extension cohort of 14 patients (mean age 57; range 30-78, gender 8M/6F) with specific RR-AML subtypes predicted to be more sensitive based upon preclinical studies, was also enrolled (AML MLL-translocated n=10; acute erythroleukemia/M6 n=4). At data cut-off (31 July 2016), 131 AEs and 27 SAEs have been reported. Eight SAEs were considered related to treatment, including a differentiation syndrome in two patients. PK and PD analyses are ongoing. For response assessment, 14 patients were evaluable. Objective responses were seen in 5/14 patients (36%): two patients with t(9;11) exhibited stable disease and three a partial response (one MLL after 3 cycles, and two M6). Importantly, there was evidence of morphologic blast differentiation in blood and/or BM in 9/14 patients (5 MLL and 4 M6). In summary, ORY-1001 at the recommended dose is well tolerated and promotes blast cell differentiation in 64% of patients. This, together with the partial responses observed, suggest that LSD1 inhibition may be a possible therapy for some AML patients. Disclosures Somervaille: Novartis: Consultancy, Honoraria; Imago Biosciences: Consultancy. Pigneux:Agios: Consultancy, Honoraria; Sunesis: Consultancy, Honoraria. Recher:Celgene, Sunesis, Amgen, Novartis: Membership on an entity's Board of Directors or advisory committees; Celgene, Sunesis, Amgen, Novartis, Chugai: Research Funding. Molinero:Oryzon Genomics: Employment, Equity Ownership. Mascaro:Oryzon Genomics: Employment. Maes:Oryzon Genomics: Employment, Equity Ownership.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.